Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 27, 2024; 16(7): 1009-1017
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years
Tung Huynh, Delana MyAn Bui, Tina Xiwen Zhou, Ke-Qin Hu
Tung Huynh, Department of Pharmacy, University of California Irvine Medical Center, Orange, CA 92868, United States
Delana MyAn Bui, University of Houston, Houston, TX 77204, United States
Tina Xiwen Zhou, Chicago Medical School at Rosalind Franklin University, North Chicago, IL 60064, United States
Ke-Qin Hu, Division of Gastroenterology and Hepatology, University of California Irvine, School of Medicine, Orange, CA 92868, United States
Author contributions: Hu KQ and Huynh T contributed to study design, data collection and analysis; Huynh T, Bui DM, and Zhou TX contributed in manuscript preparation; Hu KQ and Huynh T were responsible for final writing and editing; all authors have reviewed and approved the final version and agreed to be accountable for the work’s integrity.
Institutional review board statement: This study was approved by Institutional Review Board of University of California Irvine.
Informed consent statement: Informed consent for this retrospective study was waived.
Conflict-of-interest statement: Hu KQ is on the Speaker Bureau for Gilead. Huynh T, Bui DM, and Zhou TX reported no conflict of interests related to this study.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ke-Qin Hu, MD, FAASLD, Director, Professor, Division of Gastroenterology and Hepatology, University of California Irvine, School of Medicine, 101 The City Drive, Building 22C, Room 1503, Orange, CA 92868, United States. kqhu@uci.edu
Received: March 11, 2024
Revised: June 3, 2024
Accepted: June 27, 2024
Published online: July 27, 2024
Processing time: 137 Days and 2 Hours
Core Tip

Core Tip: Tenofovir disoproxil fumarate (TDF), entecavir, and tenofovir alafenamide (TAF) have been used as first-line therapy for chronic hepatitis B. In this study, we assessed the effect of TDF switching to TAF for 3 years (144 weeks) on dynamic changes of alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST to platelet ratio index (APRI), fibrosis-4 (FIB-4) scores and shear wave elastography (SWE) reading. Our study demonstrated that switching from TDF to TAF for 3 years results in persistent mean ALT and AST reduction with high rate of normalization, and also hepatic fibrosis improvement assessed by mean APRI and FIB-4 scores, as well as SWE reading.